Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men
暂无分享,去创建一个
M. Rubin | A. Tewari | J. Mosquera | T. Macdonald | C. Barbieri | A. Srivastava | Zhengming Chen | B. Robinson | F. Khani | Mirjam Blattner | Kyung Park | Catherine O’Reilly | K. Park
[1] John T. Wei,et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. , 2013, Urologic oncology.
[2] A. Zoubeidi,et al. Dual inhibition of autophagy and the AKT pathway in prostate cancer , 2013, Autophagy.
[3] M. Rubin,et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover , 2013, Proceedings of the National Academy of Sciences.
[4] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[5] Aliccia Bollig-Fischer,et al. Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[6] U. Stenman,et al. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells , 2013, Prostate Cancer and Prostatic Diseases.
[7] Michael N. Ferrandino,et al. Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center , 2012, Prostate Cancer and Prostatic Diseases.
[8] M. Truong,et al. Toward the detection of prostate cancer in urine: a critical analysis. , 2013, The Journal of urology.
[9] John T. Wei,et al. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. , 2012, American journal of clinical pathology.
[10] S. Srivastava,et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. , 2012, Urology.
[11] W. Hahn,et al. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis , 2012, Proceedings of the National Academy of Sciences.
[12] J. Hicks,et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer , 2012, Modern Pathology.
[13] T. Clackson,et al. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models , 2012, International journal of oncology.
[14] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[15] M. Soloway,et al. Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. , 2012, The Journal of urology.
[16] J. Squire,et al. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration‐resistant prostate cancer , 2012, Histopathology.
[17] Nallasivam Palanisamy,et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.
[18] J. Squire,et al. PTEN deletion and heme oxygenase‐1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome , 2011, The Journal of pathology.
[19] S. Freedland,et al. Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men , 2011, Prostate Cancer and Prostatic Diseases.
[20] B. O’Malley,et al. Tumor Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Coactivator SRC-3/AIB1 , 2011, Oncogene.
[21] M. Rubin,et al. TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.
[22] S. Varambally,et al. Therapeutic Targeting of SPINK1-Positive Prostate Cancer , 2011, Science Translational Medicine.
[23] J. D’Armiento,et al. Tuberculosis Immunopathology: The Neglected Role of Extracellular Matrix Destruction , 2011, Science Translational Medicine.
[24] J. Squire,et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer , 2011, BJU international.
[25] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[26] V. Apprey,et al. Identification of Differentially Methylated Genes in Normal Prostate Tissues from African American and Caucasian Men , 2010, Clinical Cancer Research.
[27] Tapio Visakorpi,et al. Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer , 2010, Clinical Cancer Research.
[28] W. Gerald,et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.
[29] J Wade Harper,et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. , 2009, Molecular cell.
[30] B. O’Malley,et al. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family , 2009, Nature Reviews Cancer.
[31] Arul M Chinnaiyan,et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.
[32] O. Ludkovski,et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.
[33] John T. Wei,et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.
[34] U. Stenman,et al. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. , 2007, European urology.
[35] M. Shen,et al. Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.
[36] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[37] T. Kute,et al. Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[38] A. Ziaee,et al. Role of PTEN gene in progression of prostate cancer. , 2007, Urology journal.
[39] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[40] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[41] W. Isaacs,et al. Explaining racial differences in prostate cancer in the United States: Sociology or biology? , 2005, The Prostate.
[42] Desok Kim,et al. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. , 2003, The Journal of urology.
[43] C. Longcope,et al. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[44] Simon P. Kim,et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] E. Rimm,et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. , 2000, Journal of the National Cancer Institute.
[46] M. Banerjee,et al. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. , 2000, Urology.
[47] 永井康雄. Identification of a novel nuclear speckle-type protein,SPOP(新規核speckle型タンパク質,SPOPの同定) , 1998 .
[48] 永井 康雄. Identification of a novel nuclear speckle-type protein, SPOP , 1998 .
[49] G. A. Alexander,et al. Prostate cancer treatment outcome in blacks and whites: a summary of the literature. , 1998, Seminars in urologic oncology.
[50] Y. Muro,et al. Identification of a novel nuclear speckle‐type protein, SPOP , 1997, FEBS letters.
[51] L. Bernstein,et al. Serum testosterone levels in healthy young black and white men. , 1986, Journal of the National Cancer Institute.
[52] M. Streitwieser,et al. Explaining Racial Differences , 1983 .